results of the phase ii titan study of caplacizumab in patients with attp
Published 8 years ago • 369 plays • Length 3:56Download video MP4
Download video MP3
Similar videos
-
5:00
long-term results of the phase ii revive study evaluating rusfertide in patients with pv
-
1:39
update on a phase i/ii study of ziftomenib in patients with r/r aml
-
1:56
updated results of phase i/ii bruin study: pirtobrutinib in covalent btk inhibitor pretreated mcl
-
1:17
phase ii study of tosedostat in mds
-
2:58
results of a phase ib study of ibrutinib obinutuzumab in r/r cll
-
8:24
how to use the cryocheck™ factor viii inhibitor kit
-
55:29
demystifying end-to-end dna sequencing solutions
-
3:07
update on the lighthouse (op-108) trial
-
2:12
results from phase i study of alnuctamab administered intravenously & subcutaneously in r/r myeloma
-
1:18
results of a phase i study of sonrotoclax for the treatment of r/r waldenström’s macroglobulinemia
-
2:14
long-term follow-up results from the rathl trial: response-adapted treatment for advanced stage hl
-
2:07
phase i/ii study of edit-301, a novel gene-edited autologous hsc medicine, in patients with scd
-
1:52
evaluating the efficacy of obinutuzumab, ibrutinib, and venetoclax in richter's transformation
-
2:42
results from a phase i study of cc-98633 in r/r myeloma
-
5:13
phase ii trial of pembrolizumab prior to allo-sct in aml
-
1:40
results from a phase i/ii study of golcadomide in r/r follicular lymphoma
-
2:01
real-world results of an in-class transition from vrd to ird in myeloma
-
3:02
durability of response & biomarker changes in the manifest study
-
2:00
update of a phase i trial investigating lintuzumab-ac225 plus venetoclax in r/r aml
-
2:41
an overview of the latest advances in hematology
-
1:30
insights into the manifest-2 study
-
1:45
a phase ii study of elritercept for lower-risk mds